Petr Kavan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Petr Kavan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer J. Knox
Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada
6 shared publications - Mustapha Tehfe
11Hematology and Medical Oncology Division, Centre Hospitalier Universitaire de Montreal, University of Montreal, Montreal, Canada
6 shared publications - Brandon Matthew Meyers
Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada
5 shared publications - Chris J. O'Callaghan
Queen’s University 22 Canadian Cancer Trials Group Kingston, Canada
5 shared publications - Christina A. Kim
CancerCare Manitoba, Winnipeg, MB R2H 2A6, Canada
5 shared publications - Daniel John Renouf
Pancreas Centre BC, Vancouver, Canada
5 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S2 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Supplementary Table S1 from Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- 18 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF9
Open AccessClinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Purpose: Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Experimental Design: ctDNA sequencing (PredicineATLAS) and clinical metadata from a cohort of 166 patients with metastatic PDAC (mPDAC) were generated as part of the PA.7 trial (NCT02879318). Patients were stratified into high CTF (>30% CTF; 35/166, 21.08%) and low CTF (131/166, 78.92%) groups for comparative analysis. Matched RNA sequencing data were available for 20 patients. Results: High CTF was associated with lower overall survival (hazard ratio = 1.87; 95% confidence interval, 1.27–2.75; P = 0.0014) as well as clinical presentation that was indicative of higher disease burden, with CTF highest in patients that had liver metastases and distant metastases including bulky lymph nodes versus patients with no liver metastases (P < 0.001). Exploratory gene expression analysis revealed a positive association between CTF and upregulation of cell cycle–related pathways, which included those involving CDK4 (P = 0.0093) and MT2A (P = 0.012), as well as glycolytic (P = 0.0028) and basal-like (P = 0.029) subtyping genes. Conclusions: These data demonstrate the heterogeneity of CTF and its associated factors in mPDAC, which converge toward an aggressive phenotype from both clinical and molecular standpoints.
- Open Access
The clinical, genomic, and transcriptomic landscape of BRAF mutant cancers
Background BRAF mutations are classified into 4 molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. Effective treatment has not been established for Class 2/3 or BRAF Fusions. We investigated whether BRAF mutation class differed according to clinical, genomic, and transcriptomic variables in cancer patients. Methods Using the AACR GENIE (v.12) cancer database, the distribution of BRAF mutation class in adult cancer patients was analyzed according to sex, age, primary race, and tumor type. Genomic alteration data and transcriptomic analysis was performed using The Cancer Genome Atlas. Results BRAF mutations were identified in 9515 (6.2%) samples among 153,834, with melanoma (31%), CRC (20.7%), and NSCLC (13.9%) being the most frequent cancer types. Class 1 harbored co-mutations outside of the MAPK pathway (TERT, RFN43) vs Class 2/3 mutations (RAS, NF1). Across all tumour types, Class 2/3 were enriched for alterations in genes involved in UV response and WNT/β-catenin. Pathway analysis revealed enrichment of WNT/β-catenin and Hedgehog signaling in non-V600 mutated CRC. Males had a higher proportion of Class 3 mutations vs. females (17.4% vs 12.3% q = 0.003). Non-V600 mutations were generally more common in older patients (aged 60+) vs younger (38% vs 15% pConclusions Class 2/3 BRAF are more present in Black, male patients with co-mutations outside of the MAPK pathway, likely requiring additional oncogenic input for tumorigenesis. Improving access to NGS and trial enrollment will help development of targeted therapies for non-V600 BRAF mutations. Statement of Translational Relevance BRAF mutations are classified in 4 categories based on molecular characteristics, but only Class 1 BRAF V600 have effective targeted treatment strategies. With increasing access to next-generation sequencing, oncologists are more frequently uncovering non-V600 BRAF mutations, where there remains a scarcity of effective therapies. Responsiveness to MAPK pathway inhibitors differs according to BRAF mutation class and primary tumor type. For this reason, we sought to determine whether key demographic, genomic, and transcriptomic differences existed between classes. This cross-sectional study analyzes the largest dataset of BRAF-mutated cancers to date. Our findings propose insights to optimize clinical trial design and patient selection in the pursuit of developing effective treatment strategies for patients whose tumors harbor non-V600 BRAF mutations. This study also offers insights into the potential of targeting alternative pathways in addition to the MAPK pathway as part of combinatorial treatment strategies.
Open AccessThe clinical, genomic, and transcriptomic landscape of BRAF mutant cancers
Background BRAF mutations are classified into 4 molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. Effective treatment has not been established for Class 2/3 or BRAF Fusions. We investigated whether BRAF mutation class differed according to clinical, genomic, and transcriptomic variables in cancer patients. Methods Using the AACR GENIE (v.12) cancer database, the distribution of BRAF mutation class in adult cancer patients was analyzed according to sex, age, primary race, and tumor type. Genomic alteration data and transcriptomic analysis was performed using The Cancer Genome Atlas. Results BRAF mutations were identified in 9515 (6.2%) samples among 153,834, with melanoma (31%), CRC (20.7%), and NSCLC (13.9%) being the most frequent cancer types. Class 1 harbored co-mutations outside of the MAPK pathway (TERT, RFN43) vs Class 2/3 mutations (RAS, NF1). Across all tumour types, Class 2/3 were enriched for alterations in genes involved in UV response and WNT/β-catenin. Pathway analysis revealed enrichment of WNT/β-catenin and Hedgehog signaling in non-V600 mutated CRC. Males had a higher proportion of Class 3 mutations vs. females (17.4% vs 12.3% q = 0.003). Non-V600 mutations were generally more common in older patients (aged 60+) vs younger (38% vs 15% pConclusions Class 2/3 BRAF are more present in Black, male patients with co-mutations outside of the MAPK pathway, likely requiring additional oncogenic input for tumorigenesis. Improving access to NGS and trial enrollment will help development of targeted therapies for non-V600 BRAF mutations. Statement of Translational Relevance BRAF mutations are classified in 4 categories based on molecular characteristics, but only Class 1 BRAF V600 have effective targeted treatment strategies. With increasing access to next-generation sequencing, oncologists are more frequently uncovering non-V600 BRAF mutations, where there remains a scarcity of effective therapies. Responsiveness to MAPK pathway inhibitors differs according to BRAF mutation class and primary tumor type. For this reason, we sought to determine whether key demographic, genomic, and transcriptomic differences existed between classes. This cross-sectional study analyzes the largest dataset of BRAF-mutated cancers to date. Our findings propose insights to optimize clinical trial design and patient selection in the pursuit of developing effective treatment strategies for patients whose tumors harbor non-V600 BRAF mutations. This study also offers insights into the potential of targeting alternative pathways in addition to the MAPK pathway as part of combinatorial treatment strategies.
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S450
493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S450
493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D
- 1 February 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (4_suppl) , 673
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.
673 Background: Folfirinox (FFX) and Gemcitabine with nab-Paclitaxel (GN) are both proven to be superior to Gemcitabine (G) in the first line treatment (1LTx) for advanced pancreatic cancer (APC). Yet, the optimal 1LTx selection nor sequential Tx (ST) has not been fully established. Therefore, the best choice for 1LTx is a matter of debate often influenced by access to drugs. This analysis was conducted to compare outcomes based on 1Ltx selection and ST in APC. Methods: We assessed patients (pts) with APC who received either FFX or GN as 1LTx during 2010-2019 at three Canadian institutions. As well as the ST used. The main objective was to assess survival. Kaplan method and log-rank test were used for survival curves. Results: This retrospective study included 231 pts; 1LTx included 143 pts on FFX and 88 pts on GN. FFX pts were predominantly male; 89(62.2%) vs 46(52.3%) and slightly younger (median age 62 vs 66) than GN. WHO performance status (PS) of 0 were 38 (28.4%) vs 14 (16.5%) and 1 were 90 (67.2%) vs 65 (76.5%) respectively. There were more grade 3-4 toxicity in FFX vs GN group: GI 55 (38.5%) vs 15 (17%) and hematologic 51 (35.4%) vs 20 (22.7%) respectively. Grade 3-4 neutropenia rates were similar in both regimens. The median PFS of FFX was 5.5 months (95% CI: 5.0-6.7) vs 5.1 (95% CI: 3.8-7.1) with GN (p=0.37). The median OS with FFX was 9.3 months (95% CI: 7.5-11.1) vs 10.2 (95% CI: 6.8-11.3) with GN (p=0.81). There were not statically significant. Table shows Tx frequency across 4LTx. 2LTx and beyond regimens included G, GN, FFX, Capecitabine, Irinotecan liposome plus 5-FU, Irinotecan and clinical trials. Conclusions: Our results revealed that pts who received 1LTx FFX or GN had similar PFS and OS even though 1LTx FFX group was younger with better PS, allowing to continue 2-4LTx more frequently when compare with 1LTx GN group. Therefore, 1LTx selection appear to have more impact in our pts rather than ST, whereas GN is less toxic and seems a preferable 1LTx choice for most pts. FFX could be reserved for young high-performance pts.
- 1 February 2020
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (4_suppl) , 673
First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective.
673 Background: Folfirinox (FFX) and Gemcitabine with nab-Paclitaxel (GN) are both proven to be superior to Gemcitabine (G) in the first line treatment (1LTx) for advanced pancreatic cancer (APC). Yet, the optimal 1LTx selection nor sequential Tx (ST) has not been fully established. Therefore, the best choice for 1LTx is a matter of debate often influenced by access to drugs. This analysis was conducted to compare outcomes based on 1Ltx selection and ST in APC. Methods: We assessed patients (pts) with APC who received either FFX or GN as 1LTx during 2010-2019 at three Canadian institutions. As well as the ST used. The main objective was to assess survival. Kaplan method and log-rank test were used for survival curves. Results: This retrospective study included 231 pts; 1LTx included 143 pts on FFX and 88 pts on GN. FFX pts were predominantly male; 89(62.2%) vs 46(52.3%) and slightly younger (median age 62 vs 66) than GN. WHO performance status (PS) of 0 were 38 (28.4%) vs 14 (16.5%) and 1 were 90 (67.2%) vs 65 (76.5%) respectively. There were more grade 3-4 toxicity in FFX vs GN group: GI 55 (38.5%) vs 15 (17%) and hematologic 51 (35.4%) vs 20 (22.7%) respectively. Grade 3-4 neutropenia rates were similar in both regimens. The median PFS of FFX was 5.5 months (95% CI: 5.0-6.7) vs 5.1 (95% CI: 3.8-7.1) with GN (p=0.37). The median OS with FFX was 9.3 months (95% CI: 7.5-11.1) vs 10.2 (95% CI: 6.8-11.3) with GN (p=0.81). There were not statically significant. Table shows Tx frequency across 4LTx. 2LTx and beyond regimens included G, GN, FFX, Capecitabine, Irinotecan liposome plus 5-FU, Irinotecan and clinical trials. Conclusions: Our results revealed that pts who received 1LTx FFX or GN had similar PFS and OS even though 1LTx FFX group was younger with better PS, allowing to continue 2-4LTx more frequently when compare with 1LTx GN group. Therefore, 1LTx selection appear to have more impact in our pts rather than ST, whereas GN is less toxic and seems a preferable 1LTx choice for most pts. FFX could be reserved for young high-performance pts.
- Open Access
- 1 December 2019
- Published by MDPI AG in Current Oncology
- Vol. 26 (6) , 748-754
A Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada
Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The objectives of the present study were to describe, for patients with mcrc, attrition across lines of systemic therapy, patterns of therapy and their timing, and KRAS status. Methods: A retrospective chart review at 6 Canadian academic centres included sequential patients who were diagnosed with mcrc from 1 January 2009 onward and who initiated first-line systemic treatment for mcrc between 1 January and 31 December 2009. Death was included as a competing risk in the analysis. Results: The analysis included 200 patients who started first-line therapy. The proportions of patients who started second-, third-, and fourth-line systemic therapy were 70%, 30%, and 15% respectively. Chemotherapy plus bevacizumab was the most common first-line combination (66%). The most common first-line regimen was folfiri plus bevacizumab. KRAS testing was performed in 103 patients (52%), and 38 of 68 patients (56%, 19% overall) with confirmed KRAS wild-type tumours received an epidermal growth factor receptor inhibitor (egfri), which was more common in later lines. Most KRAS testing occurred after initiation of second-line therapy. Conclusions: In the modern treatment era, a high proportion of patients receive at least two lines of therapy for mcrc, but only 19% receive egfri therapy. Earlier KRAS testing and therapy with an egfri might allow a greater proportion of patients to access all 5 active treatment agents.
- 1 December 2019
- Published by MDPI AG in Current Oncology
- Vol. 26 (6) , 748-754
Open AccessA Retrospective Observational Study to Estimate the Attrition of Patients across Lines of Systemic Treatment for Metastatic Colorectal Cancer in Canada
Background: Selection and sequencing of treatment regimens for individual patients with metastatic colorectal cancer (mcrc) is driven by maintaining reasonable quality of life and extending survival, as well as by access to and cost of therapies. The objectives of the present study were to describe, for patients with mcrc, attrition across lines of systemic therapy, patterns of therapy and their timing, and KRAS status. Methods: A retrospective chart review at 6 Canadian academic centres included sequential patients who were diagnosed with mcrc from 1 January 2009 onward and who initiated first-line systemic treatment for mcrc between 1 January and 31 December 2009. Death was included as a competing risk in the analysis. Results: The analysis included 200 patients who started first-line therapy. The proportions of patients who started second-, third-, and fourth-line systemic therapy were 70%, 30%, and 15% respectively. Chemotherapy plus bevacizumab was the most common first-line combination (66%). The most common first-line regimen was folfiri plus bevacizumab. KRAS testing was performed in 103 patients (52%), and 38 of 68 patients (56%, 19% overall) with confirmed KRAS wild-type tumours received an epidermal growth factor receptor inhibitor (egfri), which was more common in later lines. Most KRAS testing occurred after initiation of second-line therapy. Conclusions: In the modern treatment era, a high proportion of patients receive at least two lines of therapy for mcrc, but only 19% receive egfri therapy. Earlier KRAS testing and therapy with an egfri might allow a greater proportion of patients to access all 5 active treatment agents.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e16107
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).
E16107 Background: CALGB 80802 study determined that doxorubicin plus sorafenib did not improve survival (OS) compared to sorafenib. The association between platelet count and outcome of patients with HCC is inconsistent and controversial. A retrospective exploratory analysis evaluated the demographics, OS, time to progression (TTP), and progression free survival (PFS) by platelet count in HCC pts treated with sorafenib. Considering the negative outcome of CALGB 80802, the focus herein is on the standard of care sorafenib arm. Methods: The prognostic value of baseline platelet count was evaluated by Cox regression models, adjusting for clinical and pathological factors. Based on an average normal platelet cutoff level, patients were stratified on platelet count 9/L. Adjusted hazard ratios (HRadj) and 95% confidence intervals (CI) were reported. Results: 61 patients had platelet count 9/L and 109 had platelet count ≥150 × 109/L. Low platelet count 9/L was associated with male gender; low T stage, WBC count, ANC, and granulocyte count; high hemoglobin and bilirubin. High platelet count ≥150 × 109/L had shorter PFS and OS that did not reach statistical significance, and was significantly associated with shorter TTP (P=0.04), (Table). Conclusions: For sorafenib, TTP was significantly shorter among pts with platelet count ≥ 150 × 109/L. Platelet count < 150 × 109/L is suggestive of improved OS and PFS compared to pts with platelet count ≥ 150 × 109/L. Platelet count may be a prognostic factor of for patients with advanced HCC and warrants further study. Support: U10CA180821, U10CA180882; U10CA077202, U10CA180820, U10CA180888; Clinical trial information: NCT01015833.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , e16107
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).
E16107 Background: CALGB 80802 study determined that doxorubicin plus sorafenib did not improve survival (OS) compared to sorafenib. The association between platelet count and outcome of patients with HCC is inconsistent and controversial. A retrospective exploratory analysis evaluated the demographics, OS, time to progression (TTP), and progression free survival (PFS) by platelet count in HCC pts treated with sorafenib. Considering the negative outcome of CALGB 80802, the focus herein is on the standard of care sorafenib arm. Methods: The prognostic value of baseline platelet count was evaluated by Cox regression models, adjusting for clinical and pathological factors. Based on an average normal platelet cutoff level, patients were stratified on platelet count 9/L. Adjusted hazard ratios (HRadj) and 95% confidence intervals (CI) were reported. Results: 61 patients had platelet count 9/L and 109 had platelet count ≥150 × 109/L. Low platelet count 9/L was associated with male gender; low T stage, WBC count, ANC, and granulocyte count; high hemoglobin and bilirubin. High platelet count ≥150 × 109/L had shorter PFS and OS that did not reach statistical significance, and was significantly associated with shorter TTP (P=0.04), (Table). Conclusions: For sorafenib, TTP was significantly shorter among pts with platelet count ≥ 150 × 109/L. Platelet count < 150 × 109/L is suggestive of improved OS and PFS compared to pts with platelet count ≥ 150 × 109/L. Platelet count may be a prognostic factor of for patients with advanced HCC and warrants further study. Support: U10CA180821, U10CA180882; U10CA077202, U10CA180820, U10CA180888; Clinical trial information: NCT01015833.